Salarius Pharmaceuticals Rebrands to Decoy Therapeutics, Shifts Focus to Peptide Conjugates
Summary
Salarius Pharmaceuticals, Inc. has officially changed its corporate name to Decoy Therapeutics Inc. and its Nasdaq ticker symbol to DCOY, reflecting a strategic pivot towards developing next-generation peptide-conjugate therapeutics.
Key Events · Corporate Governance and Compliance · SLRX
-
Corporate Name Change
The company has changed its legal name from Salarius Pharmaceuticals, Inc. to Decoy Therapeutics Inc., effective January 8, 2026.
-
Ticker Symbol Change
The common stock will cease trading under 'SLRX' and begin trading under the new ticker symbol 'DCOY' on the Nasdaq Capital Market, effective January 8, 2026.
-
Strategic Re-focus
The changes reflect the company's new focus on developing novel peptide-conjugate therapeutics through a proprietary platform, leveraging AI-enabled computational infrastructure for candidate selection.
-
Pipeline Advancement
Decoy Therapeutics plans to advance its lead antiviral program into the clinic, expand its pipeline to address multi-viral threats and GPCR-targeted drug candidates, and pursue non-dilutive funding and partnerships.
Analysis · SLRX · Life Sciences
The corporate name and ticker symbol change signify a strategic pivot for the company, moving away from its previous identity to focus on a new proprietary peptide-conjugate platform. This re-branding aims to align the company's public image with its renewed emphasis on AI-enabled drug discovery for antiviral and oncology targets. For a company of this size, a clear strategic direction and re-branding can be crucial for attracting investor interest and potential partnerships, especially with a lead antiviral program already garnering attention from global health stakeholders.
At the time of this filing, SLRX was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.